Action Report A, B, and C v. Ireland- Application no 25579/2005

Three applicants, A,B and C, all of whom had crisis pregnancies, brought proceedings against Ireland before the European Court of Human Rights claiming violations of Articles 2, 3, 8, 14 and 13 of the European Convention on Human Rights. 1.In its judgment delivered on 16 December 2010 the Grand Chamber determined that there had been no violation of the Convention in relation to the first and second applicants, Ms. A and Ms. B.2.The Grand Chamber determined that there had been a violation of Article 8 of the Convention in relation to applicant Ms. C . Click here to download PDF 156kb  

Immunisation for babies just after their first birthday

This booklet provides the facts about the vaccines babies will receive just after their first birthday: the first MMR vaccine and the PCV and Hib/Men C booster vaccines.

Protease inhibitors in hepatitis C: from chronic disease to cure.

The recent publication of two controlled trials on boceprevir and three on telaprevir heralds a new era for hepatitis C therapy. Bocreprevir and telaprevir are protease inhibitors which act directly on the hepatitis C virus to inhibit replication and are referred to as direct acting antiviral agents (DAAâ?Ts). They are the first 2 such agents to be licensed but it is hoped that many more will soon follow. These are very important studies and represent a major advance in treatment for patients with chronic hepatitis C virus infection. To appreciate their significance it is important to be aware of some of the clinical features of hepatitis C virus infection. Firstly, hepatitis C exposure leads to chronic infection in approximately 70% of patients. Over time (years or decades) this may lead to chronic hepatitis, cirrhosis, liver failure and hepatocellular carcinoma. The speed of progression depends on a number of co-factors. Patients who are male, drink alcohol, are overweight, diabetic or co-infected with HIV have more rapid progression to cirrhosis8. In contrast young, non-drinking females progress more slowly... Many patients with hepatitis C attend drug treatment clinics. This group rarely receive anti-viral therapy but represents the bulk of the population at risk for complications of chronic hepatitis C. It has been shown that antiviral treatment in drug treatment centres, linked to methadone treatment, is very effective in ensuring compliance. As the drug treatment infrastructure already exists, widening its remit to include hepatitis C treatment should be cost effective. A recent large study from the United States confirmed that it is possible to provide effective anti-viral therapy for hepatitis C in primary care settings, provided there is appropriate back-up.

Meningococcal C conjugate (MenC) immunisation programme 2013 factsheet for healthcare practitioners

This factsheet provides information for healthcare practitioners on the schedule of the MenC vaccine given at three months old, just after the first birthday and age 14 to 18.�

Immunisation for babies just after their first birthday (English and translations)

This booklet provides the facts about the vaccines babies will receive just after their first birthday: the first MMR vaccine and the PCV and Hib/Men C booster vaccines.